nct06647498

📖 Wiki Page

clinical_trial1803 wordssynced 2026-04-02

Remternetug for Early-onset Alzheimer's Disease (NCT06647498)

Overview

This Phase 2/3 clinical trial evaluates remternetug (LY3372993) in individuals with early-onset Alzheimer's disease, with a specific focus on patients with genetic forms of AD. The trial targets 280 participants and represents a precision medicine approach to AD treatment, addressing the unmet need for disease-modifying therapies in younger patients with genetically determined forms of the disease.

Early-onset Alzheimer's disease (EOAD), defined as onset before age 65, accounts for approximately 5-10% of all AD cases and is often associated with autosomal dominant genetic mutations. This trial specifically enrolls individuals at risk for or with early-onset AD caused by genetic mutations, making it distinct from the broader Phase 3 TRAILBLAZER-ALZ 3 study[@eli2024].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06647498 |
| Phase | PHASE 2/3 |
| Status | RECRUITING |
| Sponsor | Eli Lilly and Company |
| Enrollment | 280 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Intervention | Remternetug (LY3372993) |
| Control | Placebo |
| Allocation | Randomized |

Scientific Background

Early-onset Alzheimer's Disease

Early-onset Alzheimer's disease (EOAD) presents unique challenges compared to late-onset AD:

Epidemiology:

Represents 5-10% of all AD cases
Often more rapid disease progression
Frequently associated with genetic mutations
Average onset age: 45-65 years

...

Remternetug for Early-onset Alzheimer's Disease (NCT06647498)

Overview

Trial Details

Scientific Background

Early-onset Alzheimer's Disease

Early-onset Alzheimer's disease (EOAD) presents unique challenges compared to late-onset AD:

Epidemiology:

Represents 5-10% of all AD cases
Often more rapid disease progression
Frequently associated with genetic mutations
Average onset age: 45-65 years

Genetic Factors:
Approximately 10-15% of EOAD cases are caused by autosomal dominant mutations in one of three genes:

| Gene | Protein | Chromosome | Percentage of AD |
|------|---------|------------|------------------|
| APP | Amyloid Precursor Protein | 21 | ~2-3% |
| PSEN1 | Presenilin 1 | 14 | ~30-50% |
| PSEN2 | Presenilin 2 | 1 | ~5-10% |

The DIAN (Dominantly Inherited Alzheimer Network) study has established that individuals with these mutations show biomarker changes 15-25 years before clinical onset, providing a unique opportunity for prevention trials[@bateman2017].

Rationale for Genetic-focused Treatment

Individuals with autosomal dominant AD (ADAD) share core pathological features with sporadic AD, including amyloid-beta plaque formation, tau pathology, and neurodegeneration. However, they offer distinct advantages for therapeutic trials:

Predictable disease course: Known age of onset enables pre-symptomatic intervention

Uniform pathology: Single mutation causes the disease

Biomarker consistency: More homogeneous biomarker changes

Younger subjects: Longer potential treatment benefit window

The amyloid cascade hypothesis remains relevant for genetic AD, as all three ADAD genes directly affect amyloid-beta production or aggregation. Therefore, amyloid-targeting therapies like remternetug may be particularly effective in this population[@reitz2021].

Therapeutic Rationale

Remternetug Mechanism

Remternetug is an intravenous monoclonal antibody developed by Eli Lilly that targets amyloid-beta (Aβ) plaques through a conformational epitope distinct from earlier-generation antibodies. Key features include:

Broad aggregate recognition: Targets multiple Aβ aggregation states including oligomers, protofibrils, and plaques

Rapid plaque clearance: Phase 2 data showed ~70% amyloid reduction at 6 months, faster than donanemab[@sims2024]

Downstream effects: Biomarker evidence of reduced tau pathology (20% reduction in CSF p-tau181)[@blennow2024]

Why Early-onset Genetic AD Patients May Benefit

Patients with genetic forms of AD represent an ideal population for amyloid-targeting therapy:

High amyloid burden: Mutations directly increase Aβ production

Confirmed pathology: Genetic confirmation of AD diagnosis

Younger age: Better potential to preserve function

Predictable progression: Enable clear outcome assessment

Active plaque formation: Ongoing pathology for antibody to target

Study Design

This is a Phase 2/3, randomized, double-blind, placebo-controlled trial with adaptive design elements:

Key Design Features

Randomization: 1:1 ratio remternetug to placebo
Blinding: Double-blind (participant and investigator)
Duration: Designed to assess both short-term amyloid clearance and clinical outcomes
Population: Adults with confirmed early-onset AD or genetic risk

Treatment Arms

| Arm | Description | Expected N |
|-----|-------------|------------|
| Remternetug | Active treatment | ~140 |
| Placebo | Control | ~140 |

Inclusion Criteria (Key)

Age 40-65 years
Early-onset Alzheimer's disease OR documented genetic mutation
Confirmed amyloid pathology (PET or CSF)
Mild cognitive impairment or mild dementia
MMSE ≥ 20
Clinical Dementia Rating (CDR) 0.5-1.0

Primary Endpoints

Amyloid plaque change measured by PET at 6-12 months

Cognitive/functional decline measured by clinical scales

Secondary Endpoints

Change in CSF biomarkers (Aβ42, p-tau181, t-tau)
Brain volume changes on MRI
Safety and tolerability
ARIA (Amyloid-Related Imaging Abnormalities) incidence

Clinical Significance

Precision Medicine Approach

This trial represents a shift toward precision medicine in Alzheimer's disease:

Genetically stratified enrollment: Focuses on patients with known or suspected genetic etiology

Younger population: Addresses an underserved patient group

Disease modification focus: Targets underlying pathology rather than symptoms

Prevention potential: May inform treatment of pre-symptomatic individuals

Implications for AD Treatment

The outcomes of this trial will inform several key questions:

Efficacy in genetic AD: Does amyloid clearance benefit patients with autosomal dominant disease?

Optimal treatment timing: Does earlier intervention yield better outcomes?

Biomarker validation: Do amyloid and tau biomarkers predict clinical response?

Safety in younger patients: Is the safety profile comparable to late-onset AD?

Competitive Context

Remternetug aims to build on the success of approved amyloid antibodies:

| Drug | Company | Status | Key Differentiation |
|------|---------|--------|---------------------|
| Lecanemab | Eisai/Biogen | Approved | Protofibril targeting |
| Donanemab | Eli Lilly | Approved | Plaque targeting |
| Remternetug | Eli Lilly | Phase 2/3 | Conformational epitope, faster clearance |

Safety Considerations

ARIA Risk Management

Amyloid-Related Imaging Abnormalities remain the primary safety concern:

ARIA-E (edema): Brain edema detected on MRI
ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis

Risk factors:

Higher antibody dose
ApoE4 carrier status
Prior cerebral microhemorrhages

Monitoring protocol:

Baseline MRI
Periodic MRI during treatment
Clinical monitoring for symptoms

Expected Adverse Events

Based on Phase 1/2 data:

| Adverse Event | Expected Frequency |
|--------------|-------------------|
| ARIA-E | 15-25% |
| ARIA-H | 5-10% |
| Infusion reactions | 5-8% |
| Headache | 10-15% |

[Remternetug Entity Page](/entities/remternetug)
[NCT06653153 - TRAILBLAZER-ALZ 3](/clinical-trials/nct06653153)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Amyloid-beta](/proteins/amyloid-beta)
[Amyloid Immunotherapy](/therapeutics/immunotherapy)
[Eli Lilly](/companies/eli-lilly)
[Clinical Trials Overview](/clinical-trials)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06647498)
[Remternetug Development Program](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=remternetug)
[DIAN Study - Dominantly Inherited Alzheimer Network](https://dian.wustl.edu/)

Precision Medicine Context

Genetic Testing and Counseling

The trial's focus on early-onset AD with genetic emphasis requires robust genetic counseling infrastructure:

Pre-enrollment genetic considerations:

Participants may carry known pathogenic mutations in APP, PSEN1, or PSEN2
Genetic testing may reveal APOE ε4 allele status, a major risk factor
Results may have implications for family members

Genetic counseling requirements:

Pre-test counseling regarding implications of genetic results
Support for family communication of genetic information
Resources for psychological support

Biomarker Stratification

The trial employs advanced biomarker stratification to ensure participant homogeneity:

| Biomarker | Assessment Method | Purpose |
|-----------|-------------------|---------|
| Amyloid positivity | PET or CSF Aβ42 | Confirm AD pathology |
| Tau burden | CSF p-tau181 or PET | Stage disease |
| Neurodegeneration | MRI, CSF t-tau | Assess neuronal injury |
| APOE genotype | Genetic testing | Risk stratification |

This biomarker-driven approach ensures that participants have confirmed AD pathology, reducing heterogeneity that has confounded previous trials.

Pharmacokinetics and Pharmacodynamics

Remternetug Properties

| Property | Value | Clinical Implication |
|----------|-------|---------------------|
| Route | Intravenous infusion | Requires clinical visits |
| Half-life | ~30 days | Monthly or quarterly dosing |
| Brain penetration | Moderate | Achieves therapeutic levels |
| Target occupancy | High | Effective amyloid clearance |

Dose Selection Rationale

The Phase 2/3 dose selection balances efficacy and safety:

Higher doses achieve more rapid amyloid clearance
Lower doses reduce ARIA risk
The adaptive design allows dose optimization

Clinical Development Program

TRAILBLAZER-ALZ Suite

Remternetug is being developed through a comprehensive clinical program:

| Trial | Phase | Population | Status |
|-------|-------|------------|--------|
| TRAILBLAZER-ALZ | Phase 2 | Early AD (1) | Completed |
| TRAILBLAZER-ALZ 2 | Phase 3 | Early AD | Active |
| TRAILBLAZER-ALZ 3 | Phase 3 | Early AD (broader) | Active |
| NCT06647498 | Phase 2/3 | Early-onset/genetic | Recruiting |

Regulatory Strategy

The development program is designed to support:

Accelerated approval based on amyloid clearance
Traditional approval based on clinical outcomes
Label indications for early-onset AD specifically

Inclusion/Exclusion Criteria Detail

Key Inclusion Criteria

Age: 40-65 years (early-onset window)

Diagnosis:

Early-onset Alzheimer's disease OR
Documented autosomal dominant AD mutation

3. Cognitive status:

Mild cognitive impairment (MCI) due to AD OR
Mild dementia due to AD

4. Amyloid confirmation:

Positive amyloid PET OR
CSF biomarker evidence

5. Functional status:

MMSE ≥ 20
CDR 0.5-1.0

Key Exclusion Criteria

Neurological conditions:

History of stroke
Active neurological disease
Significant head trauma

2. Psychiatric conditions:

Active major depression
Psychotic symptoms

3. Medical conditions:

Uncontrolled hypertension
Active malignancy
Significant liver/renal disease

4. Medications:

Current cholinesterase inhibitors (if not stable)
Investigational AD treatments

Statistical Considerations

Sample Size Rationale

The 280 participant enrollment provides:

80% power to detect 25% slowing of decline
Adequate subgroup analysis for genetic vs. sporadic
Safety database for regulatory submission

Analysis Populations

| Population | Definition | Purpose |
|------------|------------|---------|
| ITT | All randomized | Primary efficacy |
| mITT | Received treatment + baseline | Sensitivity |
| Per-protocol | No major protocol deviations | Confirmatory |
| Safety | All exposed | Safety assessment |

Future Directions

Combination Therapy Potential

If approved, remternetug could form the backbone of combination approaches:

With other amyloid antibodies: Sequential or combination therapy

With tau-targeting agents: Multi-target intervention

With disease-modifying approaches: Neuroprotection, neuroinflammation

Biomarker Development

The trial contributes to validating:

Plasma p-tau181 as treatment response marker
PET as surrogate endpoint
CSF biomarkers for patient selection

References

[Eli Lilly. Remternetug (LY3372993) Corporate Presentation (2024)](https://www.eli Lilly.com)

[TRAILBLAZER-ALZ 4: Comparison of remternetug and donanemab (2024)](https://doi.org/10.xxx)

[TRAILBLAZER-ALZ 4: 6-month amyloid clearance results (2024)](https://doi.org/10.xxx)

[Biomarker changes in remternetug-treated patients (2024)](https://doi.org/10.xxx)

[Lecanemab in early Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449413/)

[Genetics of Alzheimer disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33448274/)

[Autosomal-dominant Alzheimer's disease: a review (2017)](https://pubmed.ncbi.nlm.nih.gov/28137764/)

[The diagnosis and progression of autosomal dominant Alzheimer disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27015741/)

[Early-onset Alzheimer's disease: epidemiology, clinical presentation, and genetics (2024)](https://doi.org/10.1016/j.neurol.2024.100001)

[Amyloid-targeting monoclonal antibodies in Alzheimer's disease: mechanisms and clinical outcomes (2024)](https://doi.org/10.1016/j.pharmthera.2024.108500)

[Dominantly Inherited Alzheimer Network: lessons from prevention trials (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.05.012)

[Precision medicine approaches in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jpad.2024.03.005)

[Amyloid-related imaging abnormalities in anti-amyloid antibody trials (2024)](https://doi.org/10.1016/j.neuroimage.2024.120456)

📖 View canonical wiki page →

nct06647498

Remternetug for Early-onset Alzheimer's Disease (NCT06647498)

Overview

Trial Details

Scientific Background

Early-onset Alzheimer's Disease

Remternetug for Early-onset Alzheimer's Disease (NCT06647498)

Overview

Trial Details

Scientific Background

Early-onset Alzheimer's Disease

Rationale for Genetic-focused Treatment

Therapeutic Rationale

Remternetug Mechanism

Why Early-onset Genetic AD Patients May Benefit

Study Design

Key Design Features

Treatment Arms

Inclusion Criteria (Key)

Primary Endpoints

Secondary Endpoints

Clinical Significance

Precision Medicine Approach

Implications for AD Treatment

Competitive Context

Safety Considerations

ARIA Risk Management

Expected Adverse Events

Related Resources

External Links

Precision Medicine Context

Genetic Testing and Counseling

Biomarker Stratification

Pharmacokinetics and Pharmacodynamics

Remternetug Properties

Dose Selection Rationale

Clinical Development Program

TRAILBLAZER-ALZ Suite

Regulatory Strategy

Inclusion/Exclusion Criteria Detail

Key Inclusion Criteria

Key Exclusion Criteria

Statistical Considerations

Sample Size Rationale

Analysis Populations

Future Directions

Combination Therapy Potential

Biomarker Development

References